An experimental Covid-19 vaccine appears to offer strong protection in late-stage studies in the UK and South Africa, according to manufacturer Novavax.
The UK has secured access to 60 million doses of the NVX-CoV2373 vaccine.
The protein-based vaccine candidate was shown to be 89.3 percent effective against coronavirus in participants in its Phase 3 clinical trial in the UK.
According to Novavax, more than 15,000 people between the ages of 18 and 84 were enrolled, of whom 27 percent were over 65 years of age.
Stanley Erck, President and Chief Executive of the biotechnology company, said: “NVX-CoV2373 is the first vaccine to offer not only high clinical efficacy against Covid-19, but significant clinical efficacy against both the rapidly emerging varieties in the UK and in South Africa has. “
The study was carried out in collaboration with the UK Government’s Vaccine Taskforce. In a statement, Chairman Clive Dix said: “These are spectacular results and we are delighted to have helped Novavax develop this vaccine.
“The effectiveness against the emerging variants is also extremely encouraging.
“This is an incredible achievement that will ensure we can protect people in the UK and the rest of the world from this virus.”